The Emerging Role of Non-coding RNAs in Drug Resistance of Ovarian Cancer
Ovarian cancer is one of the most common gynecological malignancies with highest mortality rate among all gynecological malignant tumors. Advanced ovarian cancer patients can obtain a survival benefit from chemotherapy, including platinum drugs and paclitaxel. In more recent years, the administratio...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-08-01
|
Series: | Frontiers in Genetics |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fgene.2021.693259/full |
id |
doaj-3e766437fa2b4b0ba0fb8f63b05a685a |
---|---|
record_format |
Article |
spelling |
doaj-3e766437fa2b4b0ba0fb8f63b05a685a2021-09-03T13:11:21ZengFrontiers Media S.A.Frontiers in Genetics1664-80212021-08-011210.3389/fgene.2021.693259693259The Emerging Role of Non-coding RNAs in Drug Resistance of Ovarian CancerHua LanJing YuanDa ZengChu LiuXiaohui GuoJiahui YongXiangyang ZengSongshu XiaoOvarian cancer is one of the most common gynecological malignancies with highest mortality rate among all gynecological malignant tumors. Advanced ovarian cancer patients can obtain a survival benefit from chemotherapy, including platinum drugs and paclitaxel. In more recent years, the administration of poly-ADP ribose polymerase inhibitor to patients with BRCA mutations has significantly improved the progression-free survival of ovarian cancer patients. Nevertheless, primary drug resistance or the acquisition of drug resistance eventually leads to treatment failure and poor outcomes for ovarian cancer patients. The mechanism underlying drug resistance in ovarian cancer is complex and has not been fully elucidated. Interestingly, different non-coding RNAs (ncRNAs), such as circular RNAs, long non-coding RNAs and microRNAs, play a critical role in the development of ovarian cancer. Accumulating evidence has indicated that ncRNAs have important regulatory roles in ovarian cancer resistance to chemotherapy reagents and targeted therapy drugs. In this review, we systematically highlight the emerging roles and the regulatory mechanisms by which ncRNAs affect ovarian cancer chemoresistance. Additionally, we suggest that ncRNAs can be considered as potential diagnostic and prognostic biomarkers as well as novel therapeutic targets for ovarian cancer.https://www.frontiersin.org/articles/10.3389/fgene.2021.693259/fullovarian cancerdrug resistancemicroRNAlong non-coding RNAcircular RNA |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Hua Lan Jing Yuan Da Zeng Chu Liu Xiaohui Guo Jiahui Yong Xiangyang Zeng Songshu Xiao |
spellingShingle |
Hua Lan Jing Yuan Da Zeng Chu Liu Xiaohui Guo Jiahui Yong Xiangyang Zeng Songshu Xiao The Emerging Role of Non-coding RNAs in Drug Resistance of Ovarian Cancer Frontiers in Genetics ovarian cancer drug resistance microRNA long non-coding RNA circular RNA |
author_facet |
Hua Lan Jing Yuan Da Zeng Chu Liu Xiaohui Guo Jiahui Yong Xiangyang Zeng Songshu Xiao |
author_sort |
Hua Lan |
title |
The Emerging Role of Non-coding RNAs in Drug Resistance of Ovarian Cancer |
title_short |
The Emerging Role of Non-coding RNAs in Drug Resistance of Ovarian Cancer |
title_full |
The Emerging Role of Non-coding RNAs in Drug Resistance of Ovarian Cancer |
title_fullStr |
The Emerging Role of Non-coding RNAs in Drug Resistance of Ovarian Cancer |
title_full_unstemmed |
The Emerging Role of Non-coding RNAs in Drug Resistance of Ovarian Cancer |
title_sort |
emerging role of non-coding rnas in drug resistance of ovarian cancer |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Genetics |
issn |
1664-8021 |
publishDate |
2021-08-01 |
description |
Ovarian cancer is one of the most common gynecological malignancies with highest mortality rate among all gynecological malignant tumors. Advanced ovarian cancer patients can obtain a survival benefit from chemotherapy, including platinum drugs and paclitaxel. In more recent years, the administration of poly-ADP ribose polymerase inhibitor to patients with BRCA mutations has significantly improved the progression-free survival of ovarian cancer patients. Nevertheless, primary drug resistance or the acquisition of drug resistance eventually leads to treatment failure and poor outcomes for ovarian cancer patients. The mechanism underlying drug resistance in ovarian cancer is complex and has not been fully elucidated. Interestingly, different non-coding RNAs (ncRNAs), such as circular RNAs, long non-coding RNAs and microRNAs, play a critical role in the development of ovarian cancer. Accumulating evidence has indicated that ncRNAs have important regulatory roles in ovarian cancer resistance to chemotherapy reagents and targeted therapy drugs. In this review, we systematically highlight the emerging roles and the regulatory mechanisms by which ncRNAs affect ovarian cancer chemoresistance. Additionally, we suggest that ncRNAs can be considered as potential diagnostic and prognostic biomarkers as well as novel therapeutic targets for ovarian cancer. |
topic |
ovarian cancer drug resistance microRNA long non-coding RNA circular RNA |
url |
https://www.frontiersin.org/articles/10.3389/fgene.2021.693259/full |
work_keys_str_mv |
AT hualan theemergingroleofnoncodingrnasindrugresistanceofovariancancer AT jingyuan theemergingroleofnoncodingrnasindrugresistanceofovariancancer AT dazeng theemergingroleofnoncodingrnasindrugresistanceofovariancancer AT chuliu theemergingroleofnoncodingrnasindrugresistanceofovariancancer AT xiaohuiguo theemergingroleofnoncodingrnasindrugresistanceofovariancancer AT jiahuiyong theemergingroleofnoncodingrnasindrugresistanceofovariancancer AT xiangyangzeng theemergingroleofnoncodingrnasindrugresistanceofovariancancer AT songshuxiao theemergingroleofnoncodingrnasindrugresistanceofovariancancer AT hualan emergingroleofnoncodingrnasindrugresistanceofovariancancer AT jingyuan emergingroleofnoncodingrnasindrugresistanceofovariancancer AT dazeng emergingroleofnoncodingrnasindrugresistanceofovariancancer AT chuliu emergingroleofnoncodingrnasindrugresistanceofovariancancer AT xiaohuiguo emergingroleofnoncodingrnasindrugresistanceofovariancancer AT jiahuiyong emergingroleofnoncodingrnasindrugresistanceofovariancancer AT xiangyangzeng emergingroleofnoncodingrnasindrugresistanceofovariancancer AT songshuxiao emergingroleofnoncodingrnasindrugresistanceofovariancancer |
_version_ |
1717817189986205696 |